Edition:
United States

Celgene Corp (CELG.O)

CELG.O on Nasdaq

143.89USD
22 Sep 2017
Change (% chg)

$0.11 (+0.08%)
Prev Close
$143.78
Open
$143.31
Day's High
$144.19
Day's Low
$141.75
Volume
3,549,466
Avg. Vol
3,783,014
52-wk High
$144.59
52-wk Low
$96.93

Latest Key Developments (Source: Significant Developments)

Acceleron Pharma says entered into an agreement with Celgene Corp
Tuesday, 19 Sep 2017 07:51am EDT 

Sept 19 (Reuters) - Acceleron Pharma Inc :Acceleron Pharma - on September 18, 2017, co and Celgene Corporation entered into an amended and restated collaboration, license and option agreement.Acceleron Pharma -amends, restates their existing collaboration, license, option agreement, dated as of Feb. 20, 2008 and amended as of August 2, 2011.Acceleron Pharma-under amended agreement, celgene granted company worldwide rights to develop and commercialize sotatercept.Acceleron Pharma Inc - ‍all costs related to co's development and commercialization of sotatercept in pulmonary hypertension will be funded solely by co.Acceleron Pharma-Celgene agreed not to develop or commercialize in field of pulmonary hypertension any compound developed under amended agreement.Acceleron- ‍under amended agreement, Celgene will provide to co certain quantities of Celgene's existing clinical supply of sotatercept at no cost to co.Acceleron Pharma-co agreed not to develop or commercialize any compound developed under amended agreement in any field outside of pulmonary hypertension.Acceleron Pharma Inc - company has right to license, transfer or sell its rights to develop and commercialize sotatercept in pulmonary hypertension.Acceleron Pharma Inc - agreement between parties pertaining to phase 3 Therapeutic candidate Luspatercept was not amended.  Full Article

Bluebird Bio Inc initiates ‍expansion cohort of CRB-401 Phase 1 study of bb2121
Wednesday, 13 Sep 2017 08:00am EDT 

Sept 13 (Reuters) - bluebird bio Inc :bluebird bio Inc - ‍expansion cohort of crb-401 phase 1 study of bb2121, an anti-BCMA CAR T therapy, has been initiated​.bluebird bio Inc - ‍bluebird bio and Celgene Corp are jointly developing bb2121​.  Full Article

Alvogen unit confirms ANDA filing and patent challenge for generic Revlimid
Monday, 11 Sep 2017 06:54am EDT 

Sept 11 (Reuters) - Lotus Pharmaceuticals::Alvogen subsidiary confirms ANDA filing and patent challenge for generic Revlimid.Alvogen's unit Lotus Pharmaceuticals announced that Celgene filed suit on Sept 6, in U.S. District Court for district of New Jersey​.‍Lotus says Celgene's lawsuit resulted in stay of FDA approval of Lotus' ANDA for up to 30 months from date plaintiffs, Celgene, got notice of Lotus' ANDA filing​.  Full Article

Celgene provides update on the Fusion clinical program
Thursday, 7 Sep 2017 07:30am EDT 

Sept 7 (Reuters) - Celgene Corp :Celgene provides update on the Fusion clinical program.‍Patients enrolled in trials on partial clinical hold who are receiving clinical benefit from treatment as determined by investigator,may remain on treatment​.‍U.S. FDA has placed a partial clinical hold on five trials and a full clinical hold on one trial in celgene fusion program​.‍FDA has placed a partial clinical hold on five trials and a full clinical hold on one trial in celgene Fusion program​.‍Patients enrolled in trial on full clinical hold will be discontinued from treatment​.FDA decision based on risks identified in trials for pembrolizumab in patients with multiple myeloma in combination with immunomodulatory agents​.‍Clinical holds allow for additional information to be collected to further understand risk benefit profile of program​.‍No new patients will be enrolled into trials placed on hold​.‍Trial placed on full clinical hold is MEDI4736-MM-002​.  Full Article

Celgene Corp reports 5.6 percent passive stake in BeiGene as of Aug 31 - SEC filing‍​
Friday, 1 Sep 2017 06:18am EDT 

Sept 1 (Reuters) - Beigene Ltd :Celgene Corp reports 5.6 percent passive stake in BeiGene as of Aug 31 - SEC filing‍​.  Full Article

Celgene enters collaboration with BeiGene to advance inhibitor program for solid tumor cancers
Wednesday, 5 Jul 2017 09:00pm EDT 

July 5 (Reuters) - Celgene Corp :Celgene Corporation enters into global strategic immuno-oncology collaboration with BeiGene to advance PD-1 inhibitor program for solid tumor cancers.Celgene Corp says BeiGene to receive $263 million in upfront license fees and $150 million equity investment.Celgene Corp says BeiGene to acquire Celgene's commercial operations in China and exclusive license to Celgene's China cancer commercial portfolio.Celgene Corp says BeiGene retains right to develop BGB-A317 in hematology and in combination with its other portfolio compounds.Celgene Corp says Celgene will maintain a strategic and research and development presence in China dedicated to long-term commercial activities.Celgene Corp says BeiGene is eligible to receive up to $980 million in development, regulatory and sales milestone payments and royalties on future sales of BGB-A317.Celgene will acquire equity stake in BeiGene by purchasing 5.9 percent of BeiGene's ordinary shares at $4.58 per share.  Full Article

Agios Pharmaceuticals says IDHIFA NDA given PDUFA action date of Aug. 30
Tuesday, 6 Jun 2017 12:26pm EDT 

June 6 (Reuters) - Agios Pharmaceuticals Inc ::Updated data from phase 1 trial of oral IDHIFA (enasidenib) demonstrate complete responses and duration of response in patients with relapsed or refractory AML and an IDH2 mutation.Overall safety profile was consistent with previously reported data for oral IDHIFA​.IDHIFA NDA has been given a prescription drug user fee act PDUFA action date of Aug. 30, 2017.  Full Article

Celgene and Acceleron complete enrollment in MEDALIST, BELIEVE Phase 3 studies of luspatercept
Thursday, 1 Jun 2017 07:30am EDT 

June 1 (Reuters) - Celgene Corp :Celgene and Acceleron complete target enrollment in the medalist and believe Phase 3 studies of luspatercept in myelodysplastic syndromes and beta-thalassemia.Acceleron Pharma Inc - ‍companies expect to report top-line results from Phase 3 studies in mid-2018​.Acceleron Pharma Inc - ‍medalist phase 3 trial has enrolled 210 patients with lower-risk mds​.Acceleron Pharma Inc - ‍believe phase 3 trial has enrolled 300 patients with transfusion dependent beta-thalassemia​.  Full Article

Celgene on track to achieve or exceed 2020 forecast - CEO
Thursday, 27 Apr 2017 10:05am EDT 

April 27 (Reuters) - Celgene Corp :Celgene CEO says on track to achieve or exceed 2020 forecast.Celgene sees Otezla net sales rebounding, achieving full-year forecast.  Full Article

Acceleron says enrolment for late stage studies now expected to be completed in Q2
Thursday, 27 Apr 2017 07:35am EDT 

April 27 (Reuters) - Acceleron Pharma Inc :Acceleron provides clinical development updates on luspatercept program.Acceleron pharma inc says enrollment in MEDALIST and BELIEVE phase 3 studies now expected to be completed in q2 2017."we now look forward to reporting topline results from medalist and believe phase 3 studies in mid-2018".Acceleron pharma inc says acceleron and celgene also plan to initiate a third phase 3 trial of luspatercept.New phase 3 trial of luspatercept is expected to be initiated in early 2018.  Full Article

BRIEF-Acceleron Pharma says entered into an agreement with Celgene Corp

* Acceleron Pharma - on September 18, 2017, co and Celgene Corporation entered into an amended and restated collaboration, license and option agreement